Oncolytic Herpes Simplex Virus Vector G47Δ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma
Open Access
- 1 November 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (21) , 7886-7890
- https://doi.org/10.1158/1078-0432.ccr-05-1090
Abstract
Purpose: The use of oncolytic herpes simplex virus type 1 is a promising stategy for cancer treatment. We constructed herpes simplex virus type 1 vector G47Δ by deleting the α47 gene and the promoter region of US11 from G207. We now report studies demonstrating the potential of G47Δ as a therapeutic modality for prostate cancer in combination with androgen ablation.Keywords
All Related Versions
This publication has 15 references indexed in Scilit:
- Preclinical Safety Evaluation of G207, a Replication-Competent Herpes Simplex Virus Type 1, Inoculated Intraprostatically in Mice and Nonhuman PrimatesHuman Gene Therapy, 2001
- Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killingProceedings of the National Academy of Sciences, 2001
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 2000
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsThe Lancet, 2000
- Conditionally replicating herpes vectors for cancer therapyJournal of Clinical Investigation, 2000
- Systemic Antitumor Immunity in Experimental Brain Tumor Therapy Using a Multimutated, Replication-Competent Herpes Simplex VirusHuman Gene Therapy, 1999
- Local and Systemic Therapy of Human Prostate Adenocarcinoma with the Conditionally Replicating Herpes Simplex Virus Vector G207Human Gene Therapy, 1999
- FLUTAMIDE FOR CHEMOPREVENTION OF PROSTATE CANCERJournal of Urology, 1999
- Prostate Cancer Gene Therapy: Herpes Simplex Virus Thymidine Kinase Gene Transduction Followed by Ganciclovir in Mouse and Human Prostate Cancer ModelsHuman Gene Therapy, 1996
- Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomasNature Medicine, 1995